[Lymph node micrometastases in colorectal cancer].

Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lymph node (LN) micrometastases in colorectal cancer (CRC) has been discussed for a long time. Previous reports showed that micrometastases detected by immunohistochemistry (IHC) appeared to have no clinical impact, but that occult disease detected by molecular techniques such as RT-PCR might be associated with poor prognosis. At present, several factors are proposed as high risks for disease recurrence of stage II CRC, including T4 invasiveness, vascular invasion, poorly differentiated adenocarcinoma or mucinous carcinoma, tumor budding, wall perforation, and insufficient assessment of dissected LNs. However, it was reported that 75% of 24,847 stage II CRC patients retained specific risk factors, and the efficacy of chemotherapy in such patients has not been confirmed. A recent meta-analysis by Weitz et al. has concluded that occult disease was significantly associated with poor prognosis of node-negative CRC, irrespective of the detection method, i.e., IHC or RT-PCR. For efficient selection of high-risk stage II CRC patients, a prospective, large-scale clinical trial is essential using a convenient, simple molecular modality such as the one-step nucleic acid amplification assay.

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalUnknown Journal
Volume114
Issue number1
Publication statusPublished - Jan 1 2013
Externally publishedYes

Fingerprint

Neoplasm Micrometastasis
Colorectal Neoplasms
Lymph Nodes
Immunohistochemistry
Mucinous Adenocarcinoma
Polymerase Chain Reaction
Nucleic Acids
Blood Vessels
Meta-Analysis
Adenocarcinoma
Clinical Trials
Recurrence
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

[Lymph node micrometastases in colorectal cancer]. / Yamamoto, Hirofumi; Doki, Yuichiro; Mori, Masaki.

In: Unknown Journal, Vol. 114, No. 1, 01.01.2013, p. 17-21.

Research output: Contribution to journalArticle

Yamamoto, H, Doki, Y & Mori, M 2013, '[Lymph node micrometastases in colorectal cancer].', Unknown Journal, vol. 114, no. 1, pp. 17-21.
Yamamoto, Hirofumi ; Doki, Yuichiro ; Mori, Masaki. / [Lymph node micrometastases in colorectal cancer]. In: Unknown Journal. 2013 ; Vol. 114, No. 1. pp. 17-21.
@article{dfb3fae010d1465da68bc4e493dc145c,
title = "[Lymph node micrometastases in colorectal cancer].",
abstract = "Lymph node (LN) micrometastases in colorectal cancer (CRC) has been discussed for a long time. Previous reports showed that micrometastases detected by immunohistochemistry (IHC) appeared to have no clinical impact, but that occult disease detected by molecular techniques such as RT-PCR might be associated with poor prognosis. At present, several factors are proposed as high risks for disease recurrence of stage II CRC, including T4 invasiveness, vascular invasion, poorly differentiated adenocarcinoma or mucinous carcinoma, tumor budding, wall perforation, and insufficient assessment of dissected LNs. However, it was reported that 75{\%} of 24,847 stage II CRC patients retained specific risk factors, and the efficacy of chemotherapy in such patients has not been confirmed. A recent meta-analysis by Weitz et al. has concluded that occult disease was significantly associated with poor prognosis of node-negative CRC, irrespective of the detection method, i.e., IHC or RT-PCR. For efficient selection of high-risk stage II CRC patients, a prospective, large-scale clinical trial is essential using a convenient, simple molecular modality such as the one-step nucleic acid amplification assay.",
author = "Hirofumi Yamamoto and Yuichiro Doki and Masaki Mori",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "114",
pages = "17--21",
journal = "Quaternary International",
issn = "1040-6182",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - [Lymph node micrometastases in colorectal cancer].

AU - Yamamoto, Hirofumi

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Lymph node (LN) micrometastases in colorectal cancer (CRC) has been discussed for a long time. Previous reports showed that micrometastases detected by immunohistochemistry (IHC) appeared to have no clinical impact, but that occult disease detected by molecular techniques such as RT-PCR might be associated with poor prognosis. At present, several factors are proposed as high risks for disease recurrence of stage II CRC, including T4 invasiveness, vascular invasion, poorly differentiated adenocarcinoma or mucinous carcinoma, tumor budding, wall perforation, and insufficient assessment of dissected LNs. However, it was reported that 75% of 24,847 stage II CRC patients retained specific risk factors, and the efficacy of chemotherapy in such patients has not been confirmed. A recent meta-analysis by Weitz et al. has concluded that occult disease was significantly associated with poor prognosis of node-negative CRC, irrespective of the detection method, i.e., IHC or RT-PCR. For efficient selection of high-risk stage II CRC patients, a prospective, large-scale clinical trial is essential using a convenient, simple molecular modality such as the one-step nucleic acid amplification assay.

AB - Lymph node (LN) micrometastases in colorectal cancer (CRC) has been discussed for a long time. Previous reports showed that micrometastases detected by immunohistochemistry (IHC) appeared to have no clinical impact, but that occult disease detected by molecular techniques such as RT-PCR might be associated with poor prognosis. At present, several factors are proposed as high risks for disease recurrence of stage II CRC, including T4 invasiveness, vascular invasion, poorly differentiated adenocarcinoma or mucinous carcinoma, tumor budding, wall perforation, and insufficient assessment of dissected LNs. However, it was reported that 75% of 24,847 stage II CRC patients retained specific risk factors, and the efficacy of chemotherapy in such patients has not been confirmed. A recent meta-analysis by Weitz et al. has concluded that occult disease was significantly associated with poor prognosis of node-negative CRC, irrespective of the detection method, i.e., IHC or RT-PCR. For efficient selection of high-risk stage II CRC patients, a prospective, large-scale clinical trial is essential using a convenient, simple molecular modality such as the one-step nucleic acid amplification assay.

UR - http://www.scopus.com/inward/record.url?scp=84880247431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880247431&partnerID=8YFLogxK

M3 - Article

C2 - 23457940

AN - SCOPUS:84880247431

VL - 114

SP - 17

EP - 21

JO - Quaternary International

JF - Quaternary International

SN - 1040-6182

IS - 1

ER -